Open AccessUse of obinutuzumab for refractory autoimmune thrombocytopenia secondary to CLL
Author(s) -
Agrawal Rohitashva,
Munker Reinhold,
Krem Maxwell M.
Publication year - 2020
Publication title -
ejhaem
Language(s) - English
Resource type - Journals
ISSN - 2688-6146
DOI - 10.1002/jha2.78
Subject(s) - medicine , rituximab , immunology , pure red cell aplasia , cd20 , splenectomy , antibody dependent cell mediated cytotoxicity , thrombocytopenic purpura , chronic lymphocytic leukemia , autoimmune hemolytic anemia , obinutuzumab , ofatumumab , common variable immunodeficiency , thrombopoietin receptor , antibody , leukemia , immune system , monoclonal antibody , thrombopoietin , biology , haematopoiesis , bone marrow , spleen , stem cell , genetics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom